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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER2127Heart Failure and COPD: Beta-Blockers or Beta-AgonistsNathaniel M. Hawkins, Mark C. Petrie, Michael R. MacDonald, Pardeep S. Jhund, Leonardo M. Fabbri,
John Wikstrand, John J. V. McMurray
Hawkins and colleagues review the many therapeutic challenges posed by the combination of
congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD); the
preferred treatments are beta-blockers and beta-agonists, respectively. Beta-blockade appears
to be tolerable in patients with mild and fixed airflow obstruction, but the long-term impact
on pulmonary function, symptoms, and quality of life for patients with COPD is unclear.
Beta-agonists are associated with incident heart failure in patients with pulmonary disease,
and with increased mortality and hospitalization in those with CHF. The data from several
clinical trials are reviewed, but none were adequately powered to answer the many quandaries
posed by this combination of illnesses.VIEWPOINT AND COMMENTARY VIEWPOINT2139Healthcare Reform and the Threat to Independent Cardiology PracticesAlexander A. Stratienko
Stratienko reviews several recent changes in Centers for Medicare and Medicaid Services
reimbursement policies and other issues that have pressured independent cardiology groups to
seek shelter in hospital employment. Comments from White House officials and the language
of the Affordable Care Act suggest that this is intentional, with a goal of creating vertically-
integrated accountable care organizations. Stratienko argues that these large organizations,
which tend to be run by nonphysicians, may not be the best method for developing
innovative and patient-centered care delivery systems.COMMENTARY2141Cardiology Integration: Challenges and OpportunitiesRichard A. Chazal, C. Michael Valentine
Chazal and Valentine respond to the Viewpoint paper regarding the risks of forcing
independent physicians into employed positions within healthcare systems. This integration
must not mean abrogation of responsibility for the quality care of patients. If applied properly,
integration allows alignment of incentives and resources to improve care. Physician leadership
in crafting and managing proper processes can result in reductions in risk and cost. Integrated
strategies offer the opportunity to create reimbursement models that incentivize proactive care,
rather than penalize it.
(continued on page A-22)
MAY 24, 2011 (continued) A-22CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY2143EES Appear to Be Superior to SESLorenz Räber, Peter Jüni, Eveline Nüesch, Bindu Kalesan, Peter Wenaweser, Aris Moschovitis,
Ahmed A. Khattab, Maryam Bahlo, Mario Togni, Stéphane Cook, Rolf Vogel, Christian Seiler,
Bernhard Meier, Stephan Windecker
Räber and colleagues compared the safety and efficacy of the unrestricted use of everolimus-
eluting stents (EES) and sirolimus-eluting stents (SES). Propensity scoring was used to
match 1,600 patients treated with SES before 2006 and 1,532 subsequent patients treated
with EES. All-cause mortality was similar, but the risks of myocardial infarction and target
vessel revascularization were lower with EES than SES. Definite stent thrombosis was less
frequent among EES-treated patients (hazard ratio: 0.30). These nonrandomized results
suggest that EES result in improved long-term outcomes, mostly due to a lower risk of stent
thrombosis.INTERVENTIONAL CARDIOLOGY
2152Left Main Disease: Long-Term Results of PCI or CABG
Altered by Severity of Other LesionsDuk-Woo Park, Young-Hak Kim, Sung-Cheol Yun, Hae Geun Song, Jung-Min Ahn, Jun-Hyok Oh,
Won-Jang Kim, Jong-Young Lee, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park,
Seung-Jung Park
Park and colleagues compared the efficacy of drug-eluting stents (DES) to coronary artery
bypass grafting (CABG) for left main coronary artery disease according to the complexity of
atherosclerotic disease burden, measured with a SYNTAX (Synergy Between PCI With
Taxus and Cardiac Surgery) score. The 5-year risks of death and the composite of death, Q-
wave myocardial infarction, or stroke favored DES in patients with low-risk SYNTAX score;
by contrast, the 5-year risks of death and the composite outcome favored CABG in patients
with a high SYNTAX score. The relative efficacy of one modality compared to the other
appears to be strongly affected by the atherosclerotic burden, favoring DES for simple lesions
and CABG for diffusely diseased vessels.(continued on page A-24)
MAY 24, 2011 (continued) A-24CARDIOMYOPATHY2160Sodium Ion Channel Mutations May Cause Arrhythmic Dilated CardiomyopathyWilliam P. McNair, Gianfranco Sinagra, Matthew R. G. Taylor, Andrea Di Lenarda, Debra A. Ferguson,
Ernesto E. Salcedo, Dobromir Slavov, Xiao Zhu, John H. Caldwell, Luisa Mestroni, and the
Familial Cardiomyopathy Registry Research Group
SCN5A is a member of a family of voltage-gated sodium ion channels that is expressed
almost exclusively in the heart. Mutations in this gene have been linked to several arrhythmias
including Brugada syndrome. McNair and colleagues genotyped the SCN5A gene from over
300 individuals in the Familial Cardiomyopathy Registry. A total of 5 missense SCN5A
mutations were identified. A total of 93% of the SCN5A mutation carriers had an arrhythmia,
and the mutations stratified with the cardiomyopathy. These results show that mutations
affecting the sodium channel can result in dilated cardiomyopathies in addition to
predisposing to arrhythmias.Editorial Comment: Jeffrey A. Towbin, Angela Lorts, p. 2169CARDIAC IMAGING2172Aortic and Mitral Annular Calcification Linked to Brain InfarctsCarlos J. Rodriguez, Traci M. Bartz, W. T. Longstreth, Jr, Jorge R. Kizer, Eddy Barasch,
Donald M. Lloyd-Jones, John S. Gottdiener
Rodriguez and colleagues investigated the association of mitral annular calcification (MAC),
aortic annular calcification (AAC), and aortic valve sclerosis with brain infarcts. Participants
in the Cardiovascular Health Study underwent both brain magnetic resonance imaging and
echocardiography. The presence of any annular/valvular calcification, MAC alone, or AAC
alone were significantly associated with a higher prevalence of covert brain infarcts. This
relationship persisted after adjustment for multiple known stroke risk factors. Further study is
needed to understand the mechanisms linking annular/valvular calcification and stroke,
specifically whether there are microemboli related to these calcifications or they are simply a
marker of atherosclerosis.(continued on page A-25)
MAY 24, 2011 (continued) A-25PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCH2181Oral Nitrates May Protect Against Doxorubicin-Induced CardiomyopathyShu-Guang Zhu, Rakesh C. Kukreja, Anindita Das, Qun Chen, Edward J. Lesnefsky, Lei Xi
Doxorubicin is a powerful anthracycline antibiotic used to treat neoplasms, but its use is
limited by cardiotoxic side effects. Zhu and colleagues hypothesized that dietary nitrate/nitrite
supplementation might prevent doxorubicin-induced myocardial dysfunction, and they studied
it in a mouse model. The results showed that oral intake of inorganic nitrate attenuated
doxorubicin-induced ventricular dysfunction, cardiac cell death, oxidative stress, and
mitochondrial respiratory chain damage. Nitrates could be a promising therapeutic agent
against doxorubicin-induced cardiotoxicity.Editorial Comment: Andreas Daiber, Tommaso Gori, Thomas Münzel, p. 2190PRE-CLINICAL RESEARCH2194Mycophenolate Mofetil Decreases Atherosclerotic Lesion Size in MiceSibylle von Vietinghoff, Ekaterina K. Koltsova, Javier Mestas, Cody J. Diehl, Joseph L. Witztum, Klaus Ley
von Vietinghoff and colleagues studied whether mycophenolate mofetil (MMF), which
inhibits lymphocyte proliferation, also inhibits atherosclerosis development in apolipoprotein-
E–deficient (Apoe/) mice. Macroscopic and histologic aortic atherosclerotic lesions were
significantly decreased in MMF-treated mice. While systemic immunoglobulin G directed
against low-density lipoproteins was not affected, the T-cell cytokine interleukin (IL)-17 was
significantly reduced in the plasma of MMF-treated mice. Further studies confirmed the link
between IL-17 and inflammatory macrophages. These results suggest the therapeutic
potential of MMF for treating atherosclerosis and help to clarify the link between
lymphocytes and atherosclerosis.
